Cyclosporine Neoral in liver transplant recipients.
Levy
G
G
Toronto Hospital-University of Toronto, Ontario, Canada.
Rochon
J
J
Freeman
D
D
Wong
P Y
PY
Banks
L
L
Roach
C
C
Engel
K
K
Grant
D
D
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002779:Cholestasis / Q000150:complications*; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007408:Intestinal Absorption; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008657:Metabolic Clearance Rate; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D008775:Methylprednisolone